Senate introduces BINSA bill to tighten review of China biotech and pharma transactions

The U.S. Senate has introduced the Biotech Innovation and National Security Act (BINSA), a bill that would tighten oversight of biotech and pharmaceutical transactions involving China.

The proposal builds on a similar measure first drafted by the House, and it would shift the responsibility for screening deals to the Treasury Department.

Senator Elissa Slotkin (D-MI) and other sponsors describe the legislation as contentious, noting that it could limit cross-border collaborations and affect ongoing investments.